GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (NSE:JUBLPHARMA) » Definitions » ROE % Adjusted to Book Value

Jubilant Pharmova (NSE:JUBLPHARMA) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Jubilant Pharmova ROE % Adjusted to Book Value?

Jubilant Pharmova's ROE % for the quarter that ended in Dec. 2024 was 6.79%. Jubilant Pharmova's PB Ratio for the quarter that ended in Dec. 2024 was N/A. Jubilant Pharmova's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.


Jubilant Pharmova ROE % Adjusted to Book Value Historical Data

The historical data trend for Jubilant Pharmova's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova ROE % Adjusted to Book Value Chart

Jubilant Pharmova Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.55 7.06 7.09 -1.39 0.86

Jubilant Pharmova Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.60 - 2.25 -

Competitive Comparison of Jubilant Pharmova's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jubilant Pharmova's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's ROE % Adjusted to Book Value falls into.


;
;

Jubilant Pharmova ROE % Adjusted to Book Value Calculation

Jubilant Pharmova's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=1.42% / 1.66
=0.86%

Jubilant Pharmova's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=6.79% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jubilant Pharmova ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Jubilant Pharmova's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Jubilant Pharmova Business Description

Traded in Other Exchanges
Address
1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.

Jubilant Pharmova Headlines

No Headlines